

# ASX ANNOUNCEMENT

20 January 2021

## FIRST TRANCHE CLOSING UNDER AGREEMENT WITH MERCER

### **Brisbane, Australia and Minneapolis, USA.**

Anteris Technologies Ltd (ASX: AVR; **Anteris** or **the Company**) announces that the first tranche closing under the convertible security and share purchase agreement to Mercer Street Global Opportunity Fund, LLC (**Mercer**), as announced to ASX on 6 January 2021, has occurred today, raising \$2.5M before costs.

The Company has issued the following securities to Mercer:

- 291,545 fully paid ordinary shares to raise gross proceeds of \$1M; and
- first tranche convertible notes with a \$1.62M face value to raise a further \$1.5M.

As consideration for Mercer entering into the agreement with Anteris, the Company has also issued the following securities to Mercer:

- 50,000 fully paid ordinary shares; and
- 150,000 three year options to purchase new shares in the Company at an exercise price of \$10.

As set out in the announcement to ASX on 6 January 2021, the following issues of securities to Mercer remain subject to shareholder approval:

- second tranche convertible notes with \$1.08M face value to raise \$1M; and
- 350,000 three year options to purchase new shares in the Company at an exercise price of \$10 (with a fee of \$250,000 payable if the issue of these options are not approved).

ENDS

### **About Anteris Technologies Ltd (ASX: AVR)**

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with DurAVR™'s unique 3D single-piece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

#### **Anteris Technologies Ltd**

##### **Registered Office:**

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

##### **Customer Service:**

T +61 1300 550 310 | F +61 1300 972 437 | E [info@anteristech.com](mailto:info@anteristech.com) | W [anteristech.com](http://anteristech.com)

Brisbane • Minneapolis • Geneva • Malaga



**Authorisation and Additional information**

This announcement was authorised for release by the Board of Directors of Anteris Technologies Ltd.

**For more information:**

Ms Kyahn Williamson

WE Communications

E: [WE-AUAnterisTech@we-worldwide.com](mailto:WE-AUAnterisTech@we-worldwide.com)

P: +61 401 018 828

[www.anteristech.com](http://www.anteristech.com)

Twitter: @AnterisTech

Facebook: [www.facebook.com/AnterisTech](https://www.facebook.com/AnterisTech)